(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) | |||||||||
(Address of Principal Executive Offices) | (Zip Code) |
Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||
Exhibit | Description | ||||
99.1 | Press Release Dated July 24, 2023 filed as an Exhibit pursuant to Item 2.02 hereof. | ||||
104 | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. |
SUPERNUS PHARMACEUTICALS, INC. | ||||||||
DATED: July 24, 2023 | By: | /s/ Timothy C. Dec | ||||||
Timothy C. Dec Senior Vice President and Chief Financial Officer |
Cover Page |
Jul. 24, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Document Period End Date | Jul. 24, 2023 |
Entity Registrant Name | Supernus Pharmaceuticals, Inc. |
Entity Incorporation, State or Country Code | DE |
Entity Filer Name | 001-35518 |
Entity Tax Identification Number | 20-2590184 |
Entity Address, Address Line One | 9715 Key West Ave |
Entity Address, City or Town | Rockville |
Entity Address, State or Province | MD |
Entity Address, Postal Zip Code | 20850 |
City Area Code | 301 |
Local Phone Number | 838-2500 |
Title of 12(b) Security | Common Stock, $0.001 par value per share |
Trading Symbol | SUPN |
Security Exchange Name | NASDAQ |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Entity Emerging Growth Company | false |
Amendment Flag | false |
Entity Central Index Key | 0001356576 |